Kraig Biocraft Achieves Breakthrough in Continuous Protein Production
Event summary
- Kraig Biocraft Laboratories successfully isolated and immortalized silkworm posterior silk gland cells on May 20, 2026.
- The company's new platform enables continuous protein production via natural exocytosis, eliminating the need to destroy cells for protein extraction.
- Kim Thompson, CEO, highlights potential for faster production timelines, lower operating costs, and improved scalability.
- The technology represents a departure from traditional baculovirus insect cell expression systems.
The big picture
Kraig Biocraft's breakthrough in continuous protein production could redefine recombinant protein manufacturing, offering a more efficient and scalable alternative to conventional systems. The technology aligns with broader industry trends toward sustainable and cost-effective biomaterial production, potentially disrupting traditional methods. The company's recent spotlight in National Geographic underscores the growing recognition of its leadership in spider silk technology.
What we're watching
- Manufacturing Efficiency
- How Kraig Biocraft's continuous protein production will affect scalability and cost structures in recombinant protein manufacturing.
- Industry Disruption
- Whether the immortalized silk gland cell platform can challenge traditional baculovirus insect cell expression systems.
- Commercialization Pace
- The pace at which Kraig Biocraft can transition from technical breakthrough to commercial-scale production.
Related topics